• Allarity Therapeutics advanced stenoparib toward pivotal development by moving ahead with a Phase 3 manufacturing campaign, targeting completion no later than Q3 2026.
• No new clinical results were presented; program positioning draws on previously reported data indicating longer survival in advanced, platinum-resistant ovarian cancer.
• Manufacturing timeline is intended to support an expected pivotal trial in advanced ovarian cancer, aligning with FDA Fast Track status aimed at speeding a potential approval path.
• All manufacturing-related payments have been completed, removing expected near-term cash outlays tied to this supply build.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050800PRIMZONEFULLFEED1001179946) on May 05, 2026, and is solely responsible for the information contained therein.